Future studies should investigate whether PAC1 activation can enhance remyelination or neuroprotection in demyelinating disease models, potentially advancing its relevance as a therapeutic target in MS and/or other demyelinating disorders. The gene discussed is ADCYAP1R1; the disease is demyelinating disease.